Breaking: FDA Amends EUA to Expand COVID-19 Vaccine Booster Eligibility

Article

The EUA amendment was granted for both the Pfizer-BioNTech and Moderna vaccines.

All American adults who have previously been fully vaccinated against COVID-19 are now eligible to receive a COVID-19 booster shot following an amendment to prior emergency use authorizations (EUA) for the Pfizer-BioNTech and Moderna COVID-19 vaccines. 

“The FDA has determined that currently available data support expanding the eligibility of a single booster dose of the Moderna and Pfizer-BioNTech COVID-19 vaccines to individuals 18 years of age and older,” said Peter Marks, MD, PhD, director of the FDA’s Center for Biologics Evaluation and Research, in a press release.

“Streamlining the eligibility criteria and making booster doses available to all individuals 18 years of age and older will also help to eliminate confusion about who may receive a booster dose and ensure booster doses are available to all who may need one,” he added.

All adults who received a full 2-dose series of either the Pfizer-BioNTech or Moderna COVID-19 vaccine are eligible to receive a booster 6 months after their primary vaccination series. Adults who received the single-dose Janssen COVID-19 vaccine are eligible for a booster 2 months after their primary vaccine was administered. 

Immune response data from both Moderna and Pfizer-BioNTech were evaluated prior to amending the EUA. Both datasets showed antibody responses against SARS-CoV-2 in small groups of participants who received a third shot. 

Both companies are conducting postauthorization and postmarketing studies to evaluate known serious risks of myocarditis and pericarditis. 

Reference

1. Coronavirus (COVID-19) Update: FDA expands eligibility for COVID-19 vaccine boosters. News Release. FDA. November 19, 2021. https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-expands-eligibility-covid-19-vaccine-boosters 

Newsletter

Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.

Recent Videos
© 2025 MJH Life Sciences

All rights reserved.